Agreed, but would be a significant reversal of trend (although that's the point in hiring the sales staff). RG reported a 20% increase in procedures 1Q15 vs. 4Q14, and based on revenue numbers there would be slightly less than 10% increase in procedures 2Q15 vs. 1Q15 (just an estimate, see comment about product transfer costs below), and the incremental Q-to-Q increases had been declining in the quarters prior to 4Q14.
Also, I didn't get a chance to listen to the call, so I don't know if the number of procedures was reported. However, calculating from revenue (178.50 to NAVB per procedure), LifeTech's 19,000 number for 1H15 procedures is likely low, caused by their figure of 3.4M for 1H15 revenue. NAVB reported $1.84M for 1Q15 and, per the PR, $2M for 2Q15 LS revenue, summing to $3.84M 1H15 LS revenue. This would imply about 21,500 1H15 procedures (3.84M/178.50). As insideoutside has pointed out on the NAVB board, this is just an approximation due to uncertainties introduced by product transfer costs, but it does suggest the 50K procedure mark is at least a little more easily achievable than would be suggested by the LifeTech table.